Theravance Biopharma, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
TBPH$17.030.0%Stored close · as of Sep 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| | |
|---|---|
| | Page No. |
| PART I. FINANCIAL INFORMATION | |
| Item 1. Financial Statements (unaudited) | 3 |
| Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 | 3 |
| Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and six months ended June 30, 2025 and 2024 | 4 |
| Condensed Consolidated Statements of Shareholders’ Equity for the three and six months ended June 30, 2025 and 2024 | 5 |
| Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 | 6 |
| Notes to Condensed Consolidated Financial Statements | 7 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 29 |
| Item 4. Controls and Procedures | 29 |
| | |
| PART II. OTHER INFORMATION | |
| Item 1. Legal Proceedings | 30 |
| Item 1A. Risk Factors | 31 |
| Item 6. Exhibits | 64 |
| Signatures | 65 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.